Sepsis occurs when the body’s response to infection becomes uncontrolled, which can lead to organ failure and high mortality. Our approach is being developed to remove harmful substances from blood with precision using a multi‑target strategy designed to support immune balance and improve treatment options.
Sepsis is a life-threatening condition that arises when the body’s immune system overreacts to an infection. Instead of fighting the infection effectively, this uncontrolled response can lead to multiple organ failure, often resulting in septic shock and death if not treated quickly. Despite advances in critical care, sepsis remains one of the leading causes of mortality worldwide, highlighting the urgent need for new therapeutic strategies.
Current treatments for sepsis are largely supportive, focusing on stabilizing the patient and treating the underlying infection. However, there is no approved therapy that directly addresses the complex immune dysregulation driving the condition. This gap leaves clinicians with limited options to intervene effectively during the critical early phase of sepsis.
Our technology is being developed to selectively remove multiple harmful mediators from the blood in a single treatment. By targeting key drivers of immune dysregulation, the goal is to help restore balance to the immune system and reduce the risk of organ failure. This approach has been tested previously and further optimized by hemotune.
Sepsis is not a single disease with a uniform immune response, it can emerge in diverse biological profiles that evolve over time. Our development approach focuses on integrating patient stratification and immune state assessment to determine when and how the therapy can deliver the greatest benefit. By aligning treatment with individual immune profiles, we aim to move beyond one-size-fits-all interventions and bring precision medicine to one of the most urgent challenges in critical care.
